GlassScriptPhysician profile
Anthony Joseph Leone
NPI 1073596623
$36,133.87
in general payments reported to CMS, 2019-2025
49 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $1,716 · 2021: $3,554 · 2022: $2,685 · 2023: $1,537 · 2024: $1,404 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,902 · Education: $46.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,901.98 |
| Education | $46.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18,888.41 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,173.25 | 2019-2025 | Trintellix |
| Novo Nordisk INC | $1,602.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $1,322.59 | 2019-2025 | Aveir, Freestyle Libre 3 |
| Lilly USA, LLC | $1,243.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,198.85 | 2019-2025 | |
| Amgen INC. | $1,097.28 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,058.35 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Kowa Pharmaceuticals America, INC. | $899.97 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Sanofi-Aventis U.S. LLC | $735.52 | 2019-2023 | |
| Esperion Therapeutics, INC. | $702.02 | 2020-2022 | |
| Allergan, INC. | $678.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $472.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $450.92 | 2019-2022 | |
| Astellas Pharma US INC | $395.11 | 2019-2025 | Veozah |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Leone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.